Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26132533 | 0.78 | NPC1 (0.41) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| SCHEMBL10616915 | 0.75 | HIF1A (0.52) | L3MBTL1NAPRTCES2CES1KMT2A | |
| SCHEMBL8558681 | 0.75 | POLB (0.46) | LMNAKMT2AALDH1A1SMN1; SMN2HIF1A | |
| SCHEMBL30016837 | 0.73 | CES2 (0.64) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| SCHEMBL28388400 | 0.73 | CES2 (0.64) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| SCHEMBL8869716 | 0.72 | LMNA (0.47) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| SCHEMBL4820269 | 0.71 | SMN1; SMN2 (0.47) | L3MBTL1KMT2AALDH1A1SMN1; SMN2HIF1A | |
| Trifluoroacetic Acid SCHEMBL1787547 | 0.71 | L3MBTL1 (0.55) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| Trifluoroacetic Acid SCHEMBL30261497 | 0.71 | L3MBTL1 (0.55) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| Trifluoroacetic Acid SCHEMBL28314966 | 0.71 | L3MBTL1 (0.55) | LMNAL3MBTL1NAPRTP4HTMCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425608-B2 | Method of making metallopeptides | PALATIN TECHNOLOGIES, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-20060240481-A1 | Melanocortin Metallopeptode Combinatorial Libraries and Applications | PALATIN TECHNOLOGIES, INC. (US) | 2006-10-26 | — | — | US | disclosed |
| US-7049398-B1 | Melanocortin metallopeptide constructs, combinatorial libraries and applications | PALATIN TECHNOLOGIES, INC. (US) | 2006-05-23 | — | — | US | disclosed |
| US-20060083685-A1 | Opioid metallopeptide compositions and methods | PALATIN TECHNOLOGIES, INC. (US) | 2006-04-20 | — | — | US | disclosed |
| US-20060040324-A1 | Methods for making metallopeptides and metallopeptide libraries | PALATIN TECHNOLOGIES, INC. (US) | 2006-02-23 | — | — | US | disclosed |
| US-20060003386-A1 | Combinatorial library of different sequence peptide members synthesized on solid phase, where each constituent library member includes peptide sequence of three or more amino acid residues bound to solid phase characterized by sequence of two or more amino acid residues forming a metal ion-binding domain | PALATIN TECHNOLOGIES, INC. (US) | 2006-01-05 | — | — | US | disclosed |
| US-6979436-B2 | Opioid metallopeptide compositions and methods | PALATIN TECHNOLOGIES, INC. (US) | 2005-12-27 | — | — | US | disclosed |
| US-20050181447-A1 | OPIOID METALLOPEPTIDE COMPOSITIONS AND METHODS | PALATIN TECHNOLOGIES, INC. | 2005-08-18 | — | — | US | disclosed |
| EP-0831939-A4 | STRUCTURALLY DETERMINED METALLO-CONSTRUCTS AND APPLICATIONS | RHOMED INC (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20020012948-A1 | Metallopeptide combinatorial libraries and applications | PALATIN TECHNOLOGIES, INC. | 2002-01-31 | — | — | US | disclosed |
| US-6331285-B1 | PEPTIDE, PEPTIDOMIMETIC, PEPTIDE-LIKE AND METALLO-CONSTRUCTS, FOR USE IN RECEPTOR-SPECIFIC COMPOSITIONS FOR BIOLOGICAL, PHARMACEUTICAL AND RADIOPHARMACEUTICAL APPLICATIONS, CONFORMATIONALLY FIXED, | PALATIN TECHNOLOGIES, INC. | 2001-12-18 | — | — | US | disclosed |
| WO-2001036006-A1 | OPIOID METALLOPEPTIDE COMPOSITIONS AND METHODS | PALATIN TECHNOLOGIES, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
| EP-0831939-A1 | STRUCTURALLY DETERMINED METALLO-CONSTRUCTS AND APPLICATIONS | Rhomed Incorporated (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1997048444-A1 | IONTOPHORETIC DELIVERY OF CELL ADHESION INHIBITORS | BECTON DICKINSON AND COMPANY (US) | 1997-12-24 | — | — | WO | disclosed |
| WO-1996040293-A1 | STRUCTURALLY DETERMINED METALLO-CONSTRUCTS AND APPLICATIONS | RHOMED INCORPORATED (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020012948-A1 | Metallopeptide combinatorial libraries and applications | SPPL2B, METAP2, PTMS | LMNA 4247/4885L3MBTL1 434/4885NAPRT 3982/4885 |
| US-20050181447-A1 | OPIOID METALLOPEPTIDE COMPOSITIONS AND METHODS | OPRM1, OPRL1, OPRK1 | LMNA 4290/4885L3MBTL1 1222/4885NAPRT 3424/4885 |
| US-20060083685-A1 | Opioid metallopeptide compositions and methods | OPRM1, OPRL1, OPRK1 | LMNA 4233/4885L3MBTL1 1212/4885NAPRT 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.